UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

Bitcoin prices were last up 2.2% at $106,109 ... survey the firm took is showing a 36% surge in potential obstructive sleep apnea patients. ResMed makes CPAP machines and equipment to treat OSA.

Bitcoin prices were last up 2.2% at $106,109 ... a 36% surge in potential obstructive sleep apnea patients. ResMed makes CPAP machines and equipment to treat OSA. Harrison expects both weight ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines -- and digital health solutions. Key success factors for ResMed include maintaining ...

ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...

KeyBanc raised the firm’s price target on ResMed (RMD) to $280 from $266 on higher estimates and multiple, while keeping an Overweight rating ...

Citi analyst Mathieu Chevrier raised the firm’s price target on ResMed (RMD) to A$41 from A$38 and keeps a Neutral rating on the shares ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.